Cancer Biology and Pharmacology, Genome Institute of Singapore, A*STAR (Agency for Science, Technology, and Research), Biopolis, Singapore 138672, Republic of Singapore.
Mol Cell. 2011 Sep 2;43(5):798-810. doi: 10.1016/j.molcel.2011.08.011.
Both EZH2 and NF-κB contribute to aggressive breast cancer, yet whether the two oncogenic factors have functional crosstalk in breast cancer is unknown. Here, we uncover an unexpected role of EZH2 in conferring the constitutive activation of NF-κB target gene expression in ER-negative basal-like breast cancer cells. This function of EZH2 is independent of its histone methyltransferase activity but requires the physical interaction with RelA/RelB to promote the expression of NF-κB targets. Intriguingly, EZH2 acts oppositely in ER-positive luminal-like breast cancer cells and represses NF-κB target gene expression by interacting with ER and directing repressive histone methylation on their promoters. Thus, EZH2 functions as a double-facet molecule in breast cancers, either as a transcriptional activator or repressor of NF-κB targets, depending on the cellular context. These findings reveal an additional mechanism by which EZH2 promotes breast cancer progression and underscore the need for developing context-specific strategy for therapeutic targeting of EZH2 in breast cancers.
EZH2 和 NF-κB 均有助于促进侵袭性乳腺癌的发生,然而这两种致癌因子在乳腺癌中是否具有功能上的串扰尚不清楚。在这里,我们揭示了 EZH2 在赋予 ER 阴性基底样乳腺癌细胞中 NF-κB 靶基因表达组成性激活方面的一个意外作用。EZH2 的这种功能不依赖于其组蛋白甲基转移酶活性,但需要与 RelA/RelB 发生物理相互作用,以促进 NF-κB 靶基因的表达。有趣的是,EZH2 在 ER 阳性腔细胞样乳腺癌细胞中发挥相反的作用,通过与 ER 相互作用并在其启动子上指导抑制性组蛋白甲基化,从而抑制 NF-κB 靶基因的表达。因此,EZH2 在乳腺癌中是一种双面分子,根据细胞环境,它可以作为 NF-κB 靶基因的转录激活剂或抑制剂。这些发现揭示了 EZH2 促进乳腺癌进展的另一种机制,并强调需要针对乳腺癌中 EZH2 开发特定于背景的治疗靶向策略。